Skip to content

The efficacy of cue exposure therapy on treatment outcome of stimulant use disorder

The efficacy of cue exposure therapy on treatment outcome of stimulant use disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180218038782N1
Enrollment
40
Registered
2018-09-09
Start date
2018-09-06
Completion date
Unknown
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stimulant use disorder. Other stimulant dependence

Interventions

Intervention 1: Intervention group: cue exposure treatment. Intervention 2: Control group: treatment as usual (TAU).

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: stimulant use disorder diagnosis not using any kind of drug except of nicotine within two weeks before program starting Ability of reading and writing persian language Completion of informed consent form

Exclusion criteria

Exclusion criteria: having sever suicidal ideation having psychotic symptoms having acute physical problems

Design outcomes

Primary

MeasureTime frame
Treatment outcome includes: addiction severity, craving, relapse rate, quality of life and severity of depression, anxiety and stress that will be measured by addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21). Timepoint: assessment will complete at pre-test, post-test and follow up (3 months after treatment completion). Method of measurement: addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21).

Secondary

MeasureTime frame
Addiction severity. Timepoint: pretest, post test, 3 months follow up. Method of measurement: addiction severity index (ASI).;Craving. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Desires for Drug Questionnaire (DDQ) and Obsessive Compulsive Drug Use Scale (OCDUS).;Relapse rate. Timepoint: pretest, post test, 3 months follow up. Method of measurement: urine test.;Quality of life. Timepoint: pretest, post test, 3 months follow up. Method of measurement: World Health Organization Quality of Life-Brief (WHOQOL-BREF).;Severity of depression, anxiety and stress. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Depression Anxiety Stress Scales (DASS-21).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeghdad Talebizadeh

Iran University of Medical Sciences

talebizadeh.m86@gmail.com+98 21 6655 1655

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026